Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson’s Disease and Movement Disorders

DUBLIN, Aug. 28, 2023 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 2023 International Congress of Parkinson’s Disease and…